newsletter

The Alkaloid #34: The Label Isn’t the Chemistry

Indica, sativa, hybrid: familiar labels, unreliable predictions. What cannabis chemistry research can tell us—and what it cannot.

Retail categories meet overlapping chemistry. The graphs and molecular shapes are illustrative, not laboratory results. (Illustration)

Science, culture and capital — one dose at a time

The Dose

Picture three jars on a shop counter: indica, sativa, hybrid. Before anyone opens a laboratory report, the labels seem to have organized the afternoon. One suggests the sofa; another suggests finally answering those emails.

A new systematic review in the Journal of Cannabis Research, published October 24, asks whether that confidence is earned. Across 28 peer-reviewed reports, the authors found that these retail categories are unreliable guides to composition or therapeutic effects. Some associations appeared; they did not add up to dependable predictions. [1]

That deserves a careful reading, rather than another announcement that everyone buying cannabis has been doing it wrong. A useful question for a seller is what a label can substantiate. A useful question for a reader is where description ends and a promise begins.

Quick Hits

The review combines 12 plant/product reports, one animal report and 15 human reports. That is not 28 clinical trials. [1]
A 2022 U.S. laboratory-data study found chemical groupings that did not consistently follow indica, sativa and hybrid labels. [2]
A 2021 genetics study found associations with particular terpenes, despite poor overall separation by label. A partial signal is worth keeping; it is not a complete classification. [3]

That’s the news. The analysis is below — Science Desk, Market Watch, and a closing thought.

Comic illustration of a curator holding a record sleeve at a wooden desk, with an amber ribbon flowing toward an empty recliner and headphones in an adjoining room.

The Alkaloid #36: Who DJs the Trip?

Who chooses the soundtrack for psychedelic therapy? An analysis of eight playlists finds only weak evidence for a shared musical arc, without testing whether the music helps patients.

Comic spread of a caller on a sofa and a headset-wearing listener at a laptop, joined by an amber line. Anonymous record cards overlap across the foreground.

Field Notes #15: What a Support Line Can Tell Us

A new database describes 25,419 Fireside peer-support interactions. It offers a view of help-seeking, not a league table of drug risk or proof that support works.

Comic illustration of a person sitting awake on a bed, looking toward a moonlit window. Moonlight crosses scattered papers beside a notebook with a cannabis-leaf motif.

Field Notes #14: Cannabis and Sleep, Still an Evidence Gap

Nine studies, 537 adults, and a very uncertain answer. A Cochrane review on cannabis for insomnia shows why feeling sleepy and treating insomnia need separate evidence.

Comic illustration of an alert participant in a clinic recliner beneath a fading purple and turquoise swirl, while a nurse sits at a desk below a wall clock.

The Alkaloid #35: The Shorter Trip Still Needs a Clock

A mebufotenin trial found an antidepressant signal and early discharge readiness. Its protocol still required four hours at the clinic. Those are different findings.